Prime Medicine to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Prime Medicine (Nasdaq: PRME) has announced its participation in three upcoming investor conferences in November 2024. The company will engage in fireside chats at Guggenheim's Inaugural Healthcare Innovation Conference in Boston on November 13 at 3:00 p.m. ET, the Stifel 2024 Healthcare Conference in New York on November 18 at 1:15 p.m. ET, and the Jefferies London Healthcare Conference in London on November 19 at 2:30 p.m. GMT. Live audio webcasts will be available on Prime Medicine's website, with replays accessible for 90 days after each event.

CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in the following upcoming conferences:

• Guggenheim's Inaugural Healthcare Innovation Conference: Fireside chat on Wednesday, November 13, 2024, at 3:00 p.m. ET in Boston, MA.
• Stifel 2024 Healthcare Conference: Fireside chat on Monday, November 18, 2024, at 1:15 p.m. ET in New York, NY.
• Jefferies London Healthcare Conference: Fireside chat on Tuesday, November 19, 2024 at 2:30 p.m. GMT (9:30 a.m. ET) in London, U.K.
  

Live audio webcasts of each presentation will be available under “Events & Presentations” in the News & Events section of the Company’s website at www.primemedicine.com. Replays of each webcast will be available on the Prime Medicine website for 90 days following the event.

About Prime Medicine

Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types. Taken together, Prime Editing’s versatile gene editing capabilities could unlock opportunities across thousands of potential indications.

Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around our core areas of focus: hematology, immunology and oncology, liver and lung. Across each core area, Prime Medicine is focused initially on a set of high value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path, and each expected to provide the foundation for expansion into additional opportunities. Over time, the Company intends to maximize Prime Editing’s broad and versatile therapeutic potential, as well as the modularity of the Prime Editing platform, to rapidly and efficiently expand beyond the diseases in its current pipeline, potentially including additional genetic diseases, immunological diseases, cancers, infectious diseases, and targeting genetic risk factors in common diseases, which collectively impact millions of people. For more information, please visit www.primemedicine.com.

© 2024 Prime Medicine, Inc. All rights reserved. PRIME MEDICINE, the Prime Medicine logos, and PASSIGE are trademarks of Prime Medicine, Inc. All other trademarks referred to herein are the property of their respective owners.

Investor Contact
Hannah Deresiewicz
Precision AQ
212-362-1200
hannah.deresiewicz@precisionaq.com

Media Contact
Dan Budwick, 1AB
dan@1ABmedia.com

FAQ

What investor conferences will Prime Medicine (PRME) attend in November 2024?

Prime Medicine will participate in three conferences: Guggenheim's Inaugural Healthcare Innovation Conference (Nov 13), Stifel 2024 Healthcare Conference (Nov 18), and Jefferies London Healthcare Conference (Nov 19).

When is Prime Medicine's (PRME) presentation at the Guggenheim Healthcare Conference 2024?

Prime Medicine will present at Guggenheim's Inaugural Healthcare Innovation Conference on Wednesday, November 13, 2024, at 3:00 p.m. ET in Boston, MA.

How long will Prime Medicine's (PRME) conference webcasts be available for replay?

Replays of each conference webcast will be available on Prime Medicine's website for 90 days following each event.

Where can I watch Prime Medicine's (PRME) investor conference presentations?

Live audio webcasts will be available under 'Events & Presentations' in the News & Events section of Prime Medicine's website at www.primemedicine.com.